Toggle Nav
Close
  • Menu
  • Setting

Dapagliflozin

Catalog No.
A5854
SGLT2 inhibitor,potent and selective
Grouped product items
SizePriceStock Qty
10mM (in 1mL DMSO)
$61.00
In stock
Evaluation Sample
$30.00
In stock
5mg
$55.00
In stock
25mg
$110.00
In stock
100mg
$154.00
In stock
For scientific research use only and should not be used for diagnostic or medical purposes.

Tel: +1-832-696-8203

Email: [email protected]

Worldwide Distributors

Background

Dapagliflozin (CAS 461432-26-8) is a selective inhibitor of sodium-glucose cotransporter 2 (SGLT2), an integral membrane protein primarily expressed in renal proximal tubules. Acting via specific inhibition of SGLT2-mediated glucose reabsorption, dapagliflozin facilitates urinary glucose excretion, thereby regulating plasma glucose levels. It exhibits a potent EC50 of approximately 1.1 nM for human SGLT2 and shows over 1,200-fold selectivity for hSGLT2 over hSGLT1 in vitro. Preclinical studies demonstrate improved glucose tolerance, enhanced urinary glucose excretion, and reduction of hyperglycemia in diabetic animal models. Thus, dapagliflozin serves as an important investigational molecule for type 2 diabetes research.

Chemical Properties

Physical AppearanceA yellow oil
StorageStore at -20°C
M.Wt408.87
Cas No.461432-26-8
FormulaC21H25ClO6
Solubilityinsoluble in H2O; ≥116.6 mg/mL in EtOH; ≥15.1 mg/mL in DMSO
Chemical Name(2S,3R,4R,5S,6R)-2-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-6-(hydroxymethyl)oxane-3,4,5-triol
SDFDownload SDF
Canonical SMILESCCOC1=CC=C(C=C1)CC2=C(C=CC(=C2)C3C(C(C(C(O3)CO)O)O)O)Cl
Shipping ConditionSmall Molecules with Blue Ice, Modified Nucleotides with Dry Ice.
General tips We do not recommend long-term storage for the solution, please use it up soon.

Protocol

Cell experiment:[1]

Cell lines

Chinese hamster ovary cells stably expressing human SGLT2 and SGLT1

Reaction Conditions

1.1 nM (EC50)

Applications

Dapagliflozin inhibited accumulation of radiolabeled α-methyl-D-glucopyranoside, with EC50 values of 1.1 nM for human SGLT2 (hSGLT2) and 1.4 μM for hSGLT1.

Animal experiment:[1]

Animal models

Sprague-Dawley rats

Dosage form

0.1, 1.0, and 10 mg/kg

Administered orally

Applications

In normal rats, a single oral dose of 0.1, 1.0, and 10 mg/kg of dapagliflozin induced respective losses of 550, 1100, and 1900 mg of glucose per 200 g of body weight over 24 h. In streptozotocin-induced diabetic rats, a single oral dose of 0.1 mg/kg of dapagliflozin resulted in a 55% reduction in blood glucose level. The above correlation of SGLT2 inhibition, glucosuria, and blood glucose-lowering effects suggest that selective SGLT2 inhibition by dapagliflozin holds promise as a viable approach to treat type 2 diabetes.

Note

The technical data provided above is for reference only.

References:

1. Meng W, Ellsworth BA, Nirschl AA, et al. Discovery of dapagliflozin: a potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes. Journal of Medicinal Chemistry, 2008, 51(5): 1145-1149.

Biological Activity

Description Dapagliflozin is a potent and selective inhibitor of hSGLT2 with EC50 of 1.1 nM, exhibiting 1200-fold selectivity over hSGLT1.
Targets hSGLT2          
IC50 1.1 nM (EC50)          

Quality Control

Chemical structure

Dapagliflozin

Related Biological Data

Dapagliflozin

Related Biological Data

Dapagliflozin